Characteristics | n = 287 |
---|---|
Polyarticular JIA, n (%) | 107 (37.3) |
Systemic-onset JIA, n (%) | 47 (16.4) |
Oligoarticular persistent JIA, n (%) | 63 (22.0) |
Oligoarticular extended JIA, n (%) | 48 (16.7) |
Enthesitis-related JIA, n (%) | 11 (3.8) |
Psoriatic JIA, n (%) | 11 (3.8) |
Male sex, n (%) | 104 (36.2) |
Age, yrs, median (range) | 9.0 (1.4–18.8) |
Disease duration at MTX start, yrs, median (range) | 1.4 (0.0–15.6) |
PGA, median (range) | 3.4 (0.0–10.0) |
Joints with limited motion, median (range) | 2 (0–26) |
Joints with active arthritis, median (range) | 3 (0–30) |
C-HAQ disability, mean (SD)* | 1.1 (0.7) |
C-HAQ well-being, cm, mean (SD)* | 4.3 (2.7) |
ESR, mm/h, median (range) | 24 (1–140) |
RF seropositivity, n (%)** | 23 (8.0) |
MTX dose at start (mg/m2/wk), median (range) | 9.6 (2.8–25.0) |
NSAID, n (%) | 250 (87.1) |
Sulfasalazine, n (%) | 8 (2.8) |
Oral steroids, n (%) | 43 (15.0) |
Intraarticular steroids, n (%) | 41 (14.3) |
↵* C-HAQ was assessed for 280 patients, included after 1994, when the C-HAQ was introduced in our clinic.
↵** RF was assessed for 234 patients. PGA: physician global assessment of disease activity; C-HAQ: Child Health Assessment Questionnaire; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; NSAID: nonsteroidal antiinflammatory drugs.